Your browser doesn't support javascript.
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia.
Sanchez-Pernaute, Olga; Romero-Bueno, Fredeswinda I; Selva-O'Callaghan, Albert.
  • Sanchez-Pernaute O; Rheumatology Division, Jiménez Díaz Foundation University Hospital and Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain. Electronic address: osanchez@fjd.es.
  • Romero-Bueno FI; Rheumatology Division, Jiménez Díaz Foundation University Hospital and Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain.
  • Selva-O'Callaghan A; Department of Internal Medicine, Hospital Universitari Val d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain.
Reumatol Clin (Engl Ed) ; 17(9): 556-557, 2021 11.
Article in English | MEDLINE | ID: covidwho-1487951

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cyclosporine / COVID-19 Drug Treatment / Immunosuppressive Agents Limits: Humans Language: English Journal: Reumatol Clin (Engl Ed) Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cyclosporine / COVID-19 Drug Treatment / Immunosuppressive Agents Limits: Humans Language: English Journal: Reumatol Clin (Engl Ed) Year: 2021 Document Type: Article